UCB 6352

Drug Profile

UCB 6352

Alternative Names: Anti-CSF-1R monoclonal antibody - Syndax Pharmaceuticals; SNDX-6352; UCB 6352

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator UCB
  • Developer Syndax Pharmaceuticals; UCB
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 08 May 2017 Syndax plans a multiple ascending dose (MAD) trial for Cancer
  • 15 Dec 2016 Syndax Pharmaceuticals establishes CRADA with National Cancer Institute for the development of UCB 6352 and Entinostat in Cancer
  • 10 Nov 2016 Phase-I clinical trials in Cancer (In volunteers) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top